Vertex announces primary endpoint achieved in phase 2 study of vx-864 in alpha-1 antitrypsin deficiency

Boston--(business wire)--vertex pharmaceuticals incorporated (nasdaq: vrtx) today announced that in a phase 2 proof-of-concept study, vx-864 achieved rapid, consistent and statistically significant increases in mean functional alpha-1 antitrypsin (faat) levels of 2.2 to 2.3 micromolar from baseline in people with alpha-1 antitrypsin deficiency (aatd) with the pizz genotype, across three dose groups of vx-864 compared to placebo. vx-864 was generally well tolerated in the phase 2 study. these da
VRTX Ratings Summary
VRTX Quant Ranking